Taitel M S, Kotses H, Bernstein I L, Bernstein D I, Creer T L
Ohio University, Athens 45701.
J Allergy Clin Immunol. 1995 Mar;95(3):672-6. doi: 10.1016/s0091-6749(95)70171-0.
We performed a cost-benefit analysis of a previously described self-management program for adult asthma.
Direct and indirect cost data from 47 subjects who participated in the self-management program were analyzed. In particular, costs incurred by the subjects 1 year before participation were compared with costs incurred 1 year after participation.
The cost-benefit analysis indicated that the program was beneficial, reducing the cost of asthma to each patient by $475.29. The benefit came primarily from reductions in hospital admissions (reduced from $18,488 to $1538) and income lost as a result of asthma (reduced from $11,593 to $4589). The asthma self-management program cost $208.33 per patient. Comparison of the program cost with the program benefit produced a 1:2.28 cost-benefit ratio, demonstrating that the program more than paid for itself.
A self-management program for adult asthma effectively reduced the cost associated with asthma. The findings are especially salient because the subjects' asthma was generally under good medical control when they participated in the program. The savings were therefore not the result of improved medical treatment; medical treatment was a controlled parameter, not a variable, in the self-management study. The self-management program for adult asthma was cost-beneficial.
我们对之前描述的成人哮喘自我管理项目进行了成本效益分析。
分析了47名参与自我管理项目的受试者的直接和间接成本数据。特别将受试者参与项目前1年产生的成本与参与项目后1年产生的成本进行了比较。
成本效益分析表明该项目是有益的，使每位患者的哮喘成本降低了475.29美元。效益主要来自住院次数的减少（从18488美元降至1538美元）以及因哮喘导致的收入损失的减少（从11593美元降至4589美元）。哮喘自我管理项目每位患者的成本为208.33美元。将项目成本与项目效益进行比较得出成本效益比为1:2.28，表明该项目的收益超过了成本。
成人哮喘自我管理项目有效降低了与哮喘相关的成本。这些发现尤为突出，因为受试者参与项目时其哮喘通常处于良好的医疗控制之下。因此节省的成本并非改善医疗治疗的结果；在自我管理研究中，医疗治疗是一个控制参数，而非变量。成人哮喘自我管理项目具有成本效益。
